YOLFTbeta
Aligos Therapeutics Inc

Aligos Therapeutics Inc

ALGS · NASDAQ · Healthcare / Biotechnology

2.10USD+0.12 (+6.06%)

Price History

Full chart

Market Stats

Previous Close1.98
Open2.09
Day Range1.98 – 2.25
52-Week Range3.98 – 13.69
Volume57.13K
Market Cap34.66M
P/E (TTM)0.00
Forward P/E0.00
EPS-7.76
Dividend Yield0.00%
Beta2.33
50-Day Avg5.75
200-Day Avg6.89

About

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Lawrence M. Blatt MBA, Ph.D.
  • Employees82
  • HeadquartersOne Corporate Drive, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://www.aligos.com

Leadership

  • Dr. Lawrence M. Blatt MBA, Ph.D.CEO, President & Chairman of the Board · b. 1962
  • Ms. Lesley Ann Calhoun CPAExecutive VP, CFO & COO · b. 1966
  • Dr. Julian A. Symons DPHILExecutive VP & Chief Scientific Officer · b. 1962
  • Mr. Nikhil AnejaPrincipal Accounting Officer · b. 1977
  • Ms. Laura KavanaughVP & Head of Legal
  • Ms. Kristina Engeseth M.B.A.Senior VP and Head of People & Culture
  • Dr. Sushmita M. Chanda DABT, Ph.D.Executive Vice President & Chief Development Officer · b. 1967
  • Dr. David B. Smith Ph.D.Executive VP & Head of Chemical Operations
  • Dr. Tse-I Lin Ph.D.Senior VP of Early Compound Development & Belgian Site Head
  • Dr. Kieron Wesson Ph.D.Vice President & Head of Chemistry Manufacturing Controls

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00-10.55M4.36M13.91M15.53M3.94M2.19M
Growth (%)---+141.33%+219.04%+11.66%-74.60%-44.59%
Cost of Revenue1.29M2.30M3.33M104.15M3.67M3.07M2.62M930.00K
Gross Profit-1.29M-2.30M-10.55M4.36M13.91M15.53M3.94M1.26M
Gross Margin--100.00%100.00%100.00%100.00%100.00%57.46%
Operating Expense12.37M51.74M87.29M132.68M111.49M103.66M93.10M89.24M
Operating Income-13.66M-54.04M-97.83M-128.32M-97.58M-88.13M-89.15M-87.98M
Operating Margin--927.51%-2943.82%-701.66%-567.50%-2259.92%-4024.93%
EBITDA-12.37M-49.88M-94.51M-124.54M-93.91M-83.81M-128.26M-22.95M
EBITDA Margin--895.99%-2857.15%-675.24%-539.73%-3251.15%-1049.82%
Net Income-13.93M-52.26M-108.54M-128.33M-96.05M-87.68M-131.21M-24.19M
Net Income Margin--1029.04%-2944.07%-690.63%-564.61%-3326.01%-1106.72%
R&D10.46M44.04M79.89M104.15M85.08M73.04M70.27M69.45M
R&D as % of Total Revenue---757.39%2389.38%611.76%470.35%1781.22%3177.17%
Interest Expense01.86M10.55M132.00K1.64M---
Interest Expense % of Total Revenue---100.00%3.03%11.79%---

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets107.73M146.52M265.30M235.37M146.69M151.53M70.09M88.53M
Total Liabilities121.48M211.41M45.26M50.64M42.79M59.45M99.07M34.99M
Total Equity-13.75M-64.89M220.04M184.73M103.90M92.08M-28.97M53.55M
Cash24.04M69.56M220.38M186.82M81.35M135.70M37.00M18.30M
Total Debt13.86M14.33M13.01M14.46M12.57M11.14M8.38M5.25M
Net Debt-10.17M-55.23M-207.38M-172.36M-68.77M-124.57M-28.62M-13.05M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.05M-46.77M-74.26M-115.66M-79.39M-79.00M-80.74M-82.50M
Investing Cash Flow-69.29M6.79M32.76M3.02M-26.29M44.98M-18.28M-37.83M
Financing Cash Flow99.89M85.53M192.35M78.68M164.00K88.33M355.00K101.64M
Capital Expenditure2.52M2.79M2.06M892.00K943.00K19.00K130.00K437.00K
Free Cash Flow-8.56M-49.55M-76.33M-116.55M-80.33M-79.02M-80.87M-82.94M
FCF to OCF141.59%105.96%102.78%100.77%101.19%100.02%100.16%100.53%

Earnings

Report DateSep 25, 2020Nov 25, 2020Mar 23, 2021May 10, 2021Aug 5, 2021Nov 4, 2021Mar 10, 2022May 4, 2022Aug 4, 2022Nov 2, 2022Mar 9, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Mar 12, 2024May 7, 2024Aug 6, 2024Nov 6, 2024Mar 10, 2025May 6, 2025Aug 6, 2025Nov 6, 2025Mar 5, 2026May 8, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.00-24.72-0.82-23.51-20.29-20.59-0.83-18.08-16.70-14.52-0.47-12.12-12.37-11.87-0.27-4.75-4.00-1.32-3.67-3.15-2.53-2.01-2.49-2.25-1.41-2.43
EPS Actual-1.42-13.98-1.09-18.50-19.75-19.50-0.89-21.00-11.75-11.00-0.51-13.25-10.75-10.25-0.22-5.500.75-3.07-13.105.12-1.53-3.04-1.91-2.21-0.14-
Surprise-43.45%-32.93%21.31%2.66%5.29%-7.23%-16.15%29.64%24.24%-8.51%-9.32%13.10%13.65%18.52%-15.79%118.75%-132.58%-256.95%262.54%39.53%-51.24%23.29%1.63%90.07%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap34.66M
Enterprise Value7.84M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.10
Price / Book1.09
EPS-7.76
Book Value5.11
Revenue (TTM)31.52M
Gross Profit (TTM)-56.86M
EBITDA-77.92M
Profit Margin-241.01%
Operating Margin-6.80%
Return on Equity-113.59%
Return on Assets-49.12%
Shares Outstanding5.44M
Shares Float3.70M
Beta2.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 3 analystsTarget 52.38
  • Strong Buy
    2
  • Buy
    1

Ownership Breakdown

Institutions
45.65%
Insiders
10.64%
Retail / Other
43.71%

Top Institutional Holders

  • Deep Track Capital, LP
    444.11K7.11%
  • Alyeska Investment Group, L.P.
    412.00K6.60%
  • Sio Capital Management, LLC
    327.24K5.24%
  • Marshall Wace Asset Management Ltd
    267.13K4.28%
  • Bank of America Corp
    229.75K3.68%
  • Vanguard Capital Management, LLC
    178.26K2.85%
  • Woodline Partners LP
    177.36K2.84%
  • SummitTX Capital, L.P
    148.80K2.38%
  • Renaissance Technologies Corp
    100.45K1.61%
  • Baker Bros Advisors LP
    83.06K1.33%
  • Hillhouse Capital Advisors, Ltd.
    76.25K1.22%
  • D. E. Shaw & Co LP
    66.46K1.06%
  • LPL Financial Corp
    51.50K0.82%
  • Geode Capital Management, LLC
    49.98K0.80%
  • UBS Group AG
    37.06K0.59%
  • Vanguard Fiduciary Trust Co
    28.44K0.46%
  • Dimensional Fund Advisors, Inc.
    21.04K0.34%
  • Verition Fund Managegment, LLC
    18.89K0.30%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    128.77K2.06%
  • Fidelity Extended Market Index
    22.12K0.35%

Stock Splits

  • Aug 19, 20241:25